1204033-28-2Relevant academic research and scientific papers
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available Pan-PI3-kinase and dual Pan-PI3-kinase/mTOR inhibitors for the treatment of cancer
Sutherlin, Daniel P.,Sampath, Deepak,Berry, Megan,Castanedo, Georgette,Chang, Zhigang,Chuckowree, Irina,Dotson, Jenna,Folkes, Adrian,Friedman, Lori,Goldsmith, Richard,Heffron, Tim,Lee, Leslie,Lesnick, John,Lewis, Cristina,Mathieu, Simon,Nonomiya, Jim,Olivero, Alan,Pang, Jodie,Prior, Wei Wei,Salphati, Laurent,Sideris, Steve,Tian, Qingping,Tsui, Vickie,Wan, Nan Chi,Wang, Shumei,Wiesmann, Christian,Wong, Susan,Zhu, Bing-Yan
experimental part, p. 1086 - 1097 (2010/08/05)
The PI3K/AKT/mTOR pathway has been shown to play an important role in cancer. Starting with compounds 1 and 2 (GDC-0941) as templates, (thienopyrimidin-2-yl)aminopyrimidines were discovered as potent inhibitors of PI3K or both PI3K and mTOR. Structural in
